R21/Matrix-M Malaria Vaccines
On 20th May, 2024, Pune-based Serum Institute of India (SII) shipped its first batch of the R21/Matrix-M malaria vaccine to Africa.
What is R21/Matrix-M?
- The R21//Matrix-M vaccine is the second malaria vaccine to be authorized for use in children in malaria-endemic regions, following the RTS, S/AS01 vaccine, which gained WHO recommendation in 2021.
- The vaccine has been developed through collaboration between the Jenner Institute at Oxford University and the Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology.
- R21/Matrix-M vaccine received WHO recommendation for use in children in October, 2023, followed by the announcement of its high efficacy of its Phase ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Society Watch
- 1 Revised Guidelines on Obesity Diagnosis & Treatment
- 2 National Health Mission: A Milestone in Public Health Outcomes
- 3 Fiscal Health Index 2025
- 4 Ethnographic Study of Denotified, Semi-Nomadic, and Nomadic Communities
- 5 Annual Status of Education Report (Rural) 2024
- 6 Supreme Court Bans Manual Scavenging in Metro Cities
- 7 10 Years of BBBP: Driving Cultural & Social Change
- 8 HC directs Delhi Govt. to Implement PM-ABHIM Scheme
- 9 Impact of JJM on Women Empowerment in Rural Areas
- 10 Ageing in India: Actionable Solutions